Neuro-Oncology: Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial t

Saturday, March 10, 2012

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial t

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutations, which are early and frequent genetic alterations in astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas, are specific to arginine 132 (R132). Recently, we established monoclonal antibodies (mAbs) against IDH1 mutations: anti-IDH1-R132H and anti-IDH1-R132S. However, the importance of immunohistochemistry using the combination of those mAbs has not been elucidated. For this study, 164 cases of glioma were evaluated immunohistochemically for IDH1 mutations (R132H and R132S) using anti-IDH1 mAbs (HMab-1 and SMab-1). IDH1 mutation was detected, respectively, in 9.7%, 63.6%, 51.7%, and 77.8% of primary grade IV, secondary grade IV, grade III, and grade II gliomas. For each grade of glioma, prognostic factors for progression-free survival and overall survival were evaluated using clinical and pathological parameters in addition to IDH1 immunohistochemistry. IDH1 mutation, p53 overexpression, and internexin expression, as evaluated using immunohistochemistry with clinical parameters such as degree of surgical removal and preoperative Karnofsky Performance Status (KPS), might be of greater prognostic significance than histological grading alone in grade III as well as IDH1 mutation in grade IV gliomas.

Content Type Journal Article
Category Laboratory Investigation
Pages 1-13
DOI 10.1007/s11060-012-0837-0
Authors
- Shingo Takano, Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, 305-8575 Ibaraki, Tsukuba, Japan
- Yukinari Kato, Molecular Tumor Marker Research Team, Yamagata University Global COE Program, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, 990-9585 Yamagata, Japan
- Tetsuya Yamamoto, Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, 305-8575 Ibaraki, Tsukuba, Japan
- Mika Kato Kaneko, Molecular Tumor Marker Research Team, Yamagata University Global COE Program, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, 990-9585 Yamagata, Japan
- Eiichi Ishikawa, Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, 305-8575 Ibaraki, Tsukuba, Japan
- Yuta Tsujimoto, Molecular Tumor Marker Research Team, Yamagata University Global COE Program, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, 990-9585 Yamagata, Japan
- Masahide Matsuda, Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, 305-8575 Ibaraki, Tsukuba, Japan
- Kei Nakai, Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, 305-8575 Ibaraki, Tsukuba, Japan
- Ryo Yanagiya, Molecular Tumor Marker Research Team, Yamagata University Global COE Program, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, 990-9585 Yamagata, Japan
- Shunpei Morita, Molecular Tumor Marker Research Team, Yamagata University Global COE Program, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, 990-9585 Yamagata, Japan
- Koji Tsuboi, Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, 305-8575 Ibaraki, Tsukuba, Japan
- Akira Matsumura, Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, 305-8575 Ibaraki, Tsukuba, Japan